1. The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: a systematic review and meta-analysis of randomized controlled trials;Lin;J Med Virol,2022
2. UD Food and Drug Administration. FDA updates Sotrovimab emergency use authorization, https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization; 2022 [accessed 08 November 2022].
3. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an omicron BA.1 and BA.1.1-predominant phase;Aggarwal;Int J Infect Dis,2022
4. Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5;Arora;Lancet Infect Dis,2022
5. Dougan M, Azizad M, Chen P, et al. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. medRxiv. 12 November 2022. https://www.medrxiv.org/content/10.1101/2022.03.10.22272100v1 [accessed 15 January 2023].